BHC.TO - Bausch Health Companies Inc.

Toronto - Toronto Delayed Price. Currency in CAD
28.26
+0.47 (+1.69%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close27.79
Open28.16
Bid28.21 x 0
Ask28.40 x 0
Day's Range27.85 - 28.52
52 Week Range23.60 - 36.52
Volume524,230
Avg. Volume641,329
Market Cap9.955B
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-2.61
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target Est23.55
  • Barrons.com

    Here’s What Wall Street Is Saying About General Electric and the Markopolos Report

    GE stock dropped 11% Thursday after the release of a negative report by forensic accountant Harry Markopolos. Wall Street is weighing in, and here’s what analysts and big investors are saying.

  • Bull Signal Flashing for BHC Stock After Analyst Upgrade
    Schaeffer's Investment Research

    Bull Signal Flashing for BHC Stock After Analyst Upgrade

    TD Securities upgraded the equity to "buy"

  • Bausch Health Is Struggling to Go Sideways - Risk of Being Long
    TheStreet.com

    Bausch Health Is Struggling to Go Sideways - Risk of Being Long

    For his "Executive Decision" segment on Mad Money Wednesday night, Jim Cramer sat down with Joe Papa, chairman and CEO of Bausch Health Cos. , which just posted a three-cents-a-share earnings miss but with a 1% rise in revenues. Papa said he's very excited about Bausch's eye care segment, as Bausch & Lomb remains a strong brand with intense customer loyalty.

  • PR Newswire

    Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-123 Treatment For Acne Vulgaris In Lotion Form

    PDUFA Action Date is Dec. 22, 2019 LAVAL, Quebec , Aug. 7, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription ...

  • Bausch Health Companies Inc. (BHC) Q2 2019 Earnings Call Transcript
    Motley Fool

    Bausch Health Companies Inc. (BHC) Q2 2019 Earnings Call Transcript

    BHC earnings call for the period ending August 6, 2019.

  • Bausch Health Raises Guidance, Shares Follow
    Market Realist

    Bausch Health Raises Guidance, Shares Follow

    Today, Bausch Health reported its second-quarter earnings results before the market opened. It reported revenue of $2.15 billion in the quarter.

  • Bausch Health Ups Its Full-Year Outlook After Posting Solid Organic Growth
    Motley Fool

    Bausch Health Ups Its Full-Year Outlook After Posting Solid Organic Growth

    The healthcare company reported especially strong sales growth in the second quarter for gastrointestinal drug Xifaxan.

  • Benzinga

    Bausch Health Companies Reports Q2 Earnings

    Bausch Health Companies (NYSE: BHC ) reported second-quarter sales of $2.15 billion, which met the analyst consensus estimate. This is a 1.03% increase over sales of $2.128 billion the same period last ...

  • MarketWatch

    Bausch Health's stock surges as revenue rises in line with expectations, but outlook raised

    Shares of Bausch Health Companies Inc. rallied 3.0% in premarket trading Tuesday, after the health care products company reported second-quarter revenue that rose in line with expectations and raised its full-year profit outlook. The net loss narrowed to $171 million, or 49 cents a share, from $873 million, or $2.49 a share, in the same period a year ago as operating results increased while interest expense and loss on extinguishment of debt declined. Excluding non-recurring items, adjusted net income rose to $372 million from $327 million, but the company did not provide adjusted per-share figures. Total revenue rose to $2.152 billion from $2.128 billion a year ago, in line with the FactSet consensus of $2.151 billion, as Bausch & Lomb/international sales miss expectations while Salix sales beat. For 2019, the company raised its revenue guidance range to $8.40 billion to $8.60 billion from $8.35 billion to $8.55 billion. The stock has run up 26.3% year to date through Monday, while the SPDR Health Care Select Sector ETF has gained 2.8% and the S&P 500 has advanced 13.5%.

  • PR Newswire

    Bausch Health Companies Inc. Announces Second-Quarter 2019 Results And Raises Full-Year Guidance

    LAVAL, Quebec , Aug. 6, 2019 /PRNewswire/ -- Second-Quarter 2019 Financial Results Revenues of $2.152 Billion GAAP Net Loss of $171 Million Adjusted EBITDA (non-GAAP) 1  of $880 Million GAAP Cash Flow ...

  • PR Newswire

    Bausch Health Expands Dermatology Cash-Pay Prescription Program to Walgreens Stores Nationwide

    DEERFIELD, Ill. and LAVAL, Quebec, Aug. 1, 2019 /PRNewswire/ -- Walgreens and Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced a modification to their existing fulfillment agreement to bring patients lower prices, increased transparency and convenience for many of Bausch Health's dermatology products. Under the expanded agreement, Walgreens patients will have access to select dermatology products from Bausch Health's first-of-its-kind cash-pay prescription program, Dermatology.com, at lower flat cash rates ranging from $50-$115.

  • PR Newswire

    Bausch Health Provides APRISO® Intellectual Property Litigation Update

    BRIDGEWATER, N.J., July 31, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, have agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA, Inc. ("Teva") regarding APRISO® (mesalamine) extended-release capsules 0.375g.

  • MarketWatch

    Bausch Health to reduce debt by additional $100 million using cash flow from operations

    Bausch Health Companies Inc. said Monday morning that it would be using cash flow from operations to pay down $100 million of its senior secured term loans this week. It will then have paid all mandatory amortization through the second quarter of 2020, the company said. Shares rose 1.9% in premarket trade, and the stock has gained 28.9% in the year to date through Friday. The S&P 500 has gained 20.7%.

  • PR Newswire

    Bausch Health to Reduce Debt by Additional $100 Million Using Cash Flow from Operations

    LAVAL, Quebec, July 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash flow from operations. After this payment, the Company will have paid all mandatory amortization through the second quarter of 2020. Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

  • GuruFocus.com

    Bill Miller's Hedge Fund Soars 46% -- His Largest Holdings

    The bitcoin enthusiast also has a value-based firm where most top holdings are up Continue reading...

  • PR Newswire

    Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets

    BRIDGEWATER, N.J. and NEW YORK, July 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031. Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd, had challenged the validity of and had alleged non-infringement of Claims 2 and 5 of U.S. Patent No. 8,524,276, which protects the formulation of RELISTOR® tablets.

  • PR Newswire

    Bausch + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins

    BRIDGEWATER, N.J., July 9, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Ocuvite® Eye Performance vitamins, a nutritional supplement designed to meet the changing needs of consumers while further expanding the company's eye vitamin portfolio. "Today's modern, always-on world has evolved faster than our eyes – from the blue light of computer screens and cell phones to the increased UV exposure from the sun – which can have an impact on our eye health," said Joe Gordon, U.S. president, Bausch + Lomb.

  • PR Newswire

    Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

    LAVAL, Quebec , July 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019 . Bausch ...

  • Is Bausch Health Becoming a Successful Turnaround Story?
    Market Realist

    Is Bausch Health Becoming a Successful Turnaround Story?

    Bausch Health (BHC) has gained 20.13% in the last month and is up by 38.93% in 2019 on a YTD basis.

  • Why Shares of Bausch Health Companies Rocketed Higher in June
    Motley Fool

    Why Shares of Bausch Health Companies Rocketed Higher in June

    It was one of the best-performing healthcare stocks last month. Two new product launches and a big debt repayment were the primary contributors.

  • Benzinga

    6 Times These Big Investors Probably Said 'Whoops!'

    Pershing Square Capital’s Bill Ackman has had a roller-coaster of success and failures in recent years. Perhaps no failure has been as highly publicized as his stake in Valeant Pharmaceuticals, which is now Bausch Health Companies Inc (NYSE: BHC). Ackman reportedly first took his massive stake in Valeant back in 2015 at an average price of around $196 per share.

  • Here's Why Dova Pharmaceuticals Stock Jumped Higher Today
    Motley Fool

    Here's Why Dova Pharmaceuticals Stock Jumped Higher Today

    The drugmaker's Doptelet therapy just received an expanded approval.

  • TheStreet.com

    Bausch Health Gains on Debt Reduction, Psoriasis-Lotion Launch

    gained on Tuesday after the health-sciences company said it had reduced its debt outstanding and introduced a new psoriasis-treatment lotion. The Laval, Quebec, company said it had paid down an additional $100 million of debt using cash from operations, eliminating any additional "mandatory amortization" for its fiscal 2020 first quarter. Calling the drug one of its "significant seven" -- a collection of products that could garner a predicted $1 billion in sales through 2024 -- Bausch Health expects Duobrii to be a strong revenue driver.

  • Benzinga

    Bausch Sees Clearer With Less Debt

    Bausch Health Companies Inc (NYSE: BHC ) jumped 3% on Tuesday after the company announced it has taken a major stride in paying down its massive debt load. Bausch, which changed its name from Valeant Pharmaceuticals ...